Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Infect Dis. 2006 Feb 15;42(4):541-7. Epub 2006 Jan 17.

Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.

Author information

1
Department of Infectious Diseases, Infection Control and Employee Health, MD Anderson Cancer Center, Houston, TX 77030, USA. jaadachi@mdanderson.org

Erratum in

  • Clin Infect Dis. 2006 Mar 15;42(6):896.

Abstract

Rifaximin, a virtually nonabsorbed (<0.4%) rifamycin drug, has in vitro activity against aerobic and anaerobic gram-positive and gram-negative microorganisms. Because rifaximin is nonabsorbed, systemic adverse effects are unusual, and after 3 days of therapy, the fecal level of the drug reaches 8000 microg/g. Moreover, the important selection of resistant mutants by the related drug, rifampin, has not yet been observed for rifaximin. Rifaximin has been demonstrated to reduce the duration of traveler's diarrhea secondary to noninvasive bacterial pathogens and recently has been shown to reduce the occurrence of the disease when used for chemoprophylaxis. Preliminary studies have demonstrated its potential for the treatment of other gastrointestinal disorders, such as hepatic encephalopathy. Additional studies should be performed to further define the role of rifaximin in the treatment of gastrointestinal diseases in adults and children.

PMID:
16421799
DOI:
10.1086/499950
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center